TY - JOUR
T1 - Pilot study with cisplatin, ifosfamide, and etoposide in advanced non-small-cell lung carcinoma
AU - Bidoli, P.
AU - Spinazze, S.
AU - Santoro, A.
AU - Casali, P.
AU - Bedini, A. V.
AU - Guzzon, A.
PY - 1990
Y1 - 1990
N2 - Twenty-five patients with advanced non-small-cell lung carcinoma (NSCLC) were treated with a multidrug regimen (CIV) consisting of ifosfamide (IFX), cisplatin (CDDP), and etoposide (VP-16). Twenty-four patients were evaluable for response. An objective response was detected in eight cases (33%), including one case with complete tumor response. Median duration of response was 31 weeks, and median overall survival 46 weeks, with no significant difference between responders and nonresponders. Myelosuppression and gastrointestinal side effects represented the main toxic manifestations; a toxic death and an ischemic cardiac episode were also observed. CIV seems a moderately effective regimen in NSCLC, but unlikely to provide an advantage over the widely employed two-drug combination of CDDP and VP-16.
AB - Twenty-five patients with advanced non-small-cell lung carcinoma (NSCLC) were treated with a multidrug regimen (CIV) consisting of ifosfamide (IFX), cisplatin (CDDP), and etoposide (VP-16). Twenty-four patients were evaluable for response. An objective response was detected in eight cases (33%), including one case with complete tumor response. Median duration of response was 31 weeks, and median overall survival 46 weeks, with no significant difference between responders and nonresponders. Myelosuppression and gastrointestinal side effects represented the main toxic manifestations; a toxic death and an ischemic cardiac episode were also observed. CIV seems a moderately effective regimen in NSCLC, but unlikely to provide an advantage over the widely employed two-drug combination of CDDP and VP-16.
UR - http://www.scopus.com/inward/record.url?scp=0025036321&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025036321&partnerID=8YFLogxK
M3 - Article
C2 - 2171319
AN - SCOPUS:0025036321
VL - 13
SP - 424
EP - 426
JO - American Journal of Clinical Oncology
JF - American Journal of Clinical Oncology
SN - 0277-3732
IS - 5
ER -